IL33 and neoplasm: However, as some current in-depth studies have explained, some findings suggest that IL-33/ST2 has an anticancer function that may be dependent on the TM and at particular phases of tumor progression and development (Fournié and Poupot, 2018; Shen et al., 2018; Helbig et al., 2020).